Hostname: page-component-8448b6f56d-dnltx Total loading time: 0 Render date: 2024-04-20T00:22:00.630Z Has data issue: false hasContentIssue false
  • English
  • Français

A Controlled Cross-over Study of Trimipramine and Amylobarbitone

Published online by Cambridge University Press:  29 January 2018

J. W. Hunter ,
Susanne Owen ,
Aysel Eksi  and
J. F. Scott
J. W. Hunter
Affiliation:
Late of Psychiatric Unit, Rochford General Hospital
Susanne Owen
Affiliation:
Late of Psychiatric Unit, Rochford General Hospital
Aysel Eksi
Affiliation:
Late of Psychiatric Unit, Rochford General Hospital
J. F. Scott
Affiliation:
Mathematics Division, University of Sussex, Falmer, Brighton, Sussex
Get access Rights & Permissions [Opens in a new window]

Extract

Chemically, trimipramine has an imino-benzyl nucleus and a side-chain resembling that of methotrimeprazine [5-(3-dimethyl-amino-2-methyl-propyl)-10, 11-dihydrodibenz (b, f,) azepine]. In “double blind” controlled comparisons of trimipramine and imipramine, Salzmann (1965) in 27 hospitalized depressed patients who did not require ECT, found the two drugs not significantly different in effect. Blumenthal and Seppala (1965) obtained similar results. Burns (1965), however, in 44 patients suffering from psychotic depression, found trimipramine to be significantly superior at the 5 per cent. level to imipramine in ratings of recovery from depression, anxiety and insomnia. No difference was found in the latency interval between the drugs.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 113 , Issue 499 , June 1967 , pp. 667 - 670
Copyright
Copyright © Royal College of Psychiatrists, 1967 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Blumenthal, M., and Seppälä, K. (1965). “Dubbel-blind-undersokning med Surmontil och Tofranil.” Nord. psykiat. T., 19, 385.Google Scholar
Burns, B. H. (1965). “Preliminary evaluation of a new anti-depressant, trimipramine, by a sequential method.” Brit. J. Psychiat., 111, 1155.Google Scholar
Crandell, A., Zubin, J., Mettler, F. A., and Kugelmass, N. (1956). “‘Mobility’ in chronic schizophrenia with special regard to psychosurgery.” Psychiat. Q., 30, 96.Google Scholar
Davies, D. L., and Shepherd, M. (1955). “Reserpine in the treatment of anxious and depressed patients.” Lancet, ii, 117.Google Scholar
Hamilton, M. (1960). “A rating scale for depression.” J. Neurol. Neurosurg. and Psychiat., 23, 56.Google Scholar
Hobson, R. F. (1953). “Prognostic factors in electric convulsive therapy.” Ibid., 16, 275.Google Scholar
Lambert, P. A., and Guyotat, J. (1961). “Un nouvel anti-dépresseur sédatif dérivé de l'iminod-i-benzyle: le 7162 rp.; essais théapeutiques.” Presse med., 69, 31, 1425.Google Scholar
Robin, A. A., and Enoch, M. D. (1964). “A validation study of nealbarbitone.” Brit. J. Psychiat., 110, 855.Google Scholar
Salzmann, M. M. (1965). “A controlled trial with trimipramine, a new anti-depressant drug.” Ibid., 111, 1105.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.